 SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 GLOBE NEWSWIRE -- CytomX Therapeutics, Inc. Nasdaq: CTMX, a leader in the field of conditionally activated oncology therapeutics, today announced that Phase 2 data for CX-2009, a conditionally activated antibody drug conjugate ADC targeting CD166, will be presented at the San Antonio Breast Cancer Symposium on December 8th. The poster details the results from patients treated with monotherapy praluzatamab ravtansine for the treatment of advanced HRHER2- breast cancer and triple negative breast cancer TNBC. 